NCI Trials for August 2021

The National Cancer Institute approved the following clinical research studies last month.

For further information, contact the principal investigator listed.

Phase I – 10363
A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies with or Without HIV

NCI Center for Cancer Research
Lurain, Kathryn
(301) 250-5156

Phase I/II – 10417
Clinical Evaluation of ASTX727 in Combination with Venetoclax All-Oral Therapy vs Standard of Care Cytarabine and Anthracycline Induction Chemotherapy for Younger FLT3WT Patients with ELN High- Risk Acute Myeloid Leukemia

Yale University Cancer Center LAO
Savona, Michael Robert
(615) 936-3321

Phase I/II – 10428
A Phase I/II Study of Abemaciclib in Patients with HIV-Associated and HIV-Negative Kaposi Sarcoma

NCI Center for Cancer Research
Ramaswami, Ramya
(301) 451-9018

Phase II – NRG-BN010
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma

NRG Oncology
Bagley, Stephen Joseph
(215) 614-1858

Phase III – URCC-19178
Optimizing Functional Outcomes of Older Cancer Survivors After Chemotherapy

University of Rochester NCORP Research Base
Mohile, Supriya Gupta
(585) 275-9319

Phase Pilot – AMC-111
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living with HIV: A Feasibility Study

AIDS Malignancy Consortium
Sigel, Keith Magnus
(212) 824-7558

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Judiciary News Analysis

Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

The Supreme Court last week upended one of the underpinnings of administrative law by weakening the authority of federal health agencies to rely on technical expertise as they regulate medical products, issue coverage decisions, and respond to public health crises.

July 05, 2024

Vol.50 No.27

By Matthew Bin Han Ong

Conversation with The Cancer Letter

Georgetown’s Zachary Baron on the post-Chevron era: We need guardrails about when agency expertise should be cast aside

The Supreme Court struck down the Chevron doctrine, removing one of the foundational principles of administrative law and upending the way federal agencies rely on technical subject-matter expertise. What comes next?

July 05, 2024

Vol.50 No.27

By Matthew Bin Han Ong

Guest Editorial Satire

A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.

Sometimes profoundly important public health opportunities are discovered by accident.

July 05, 2024

Vol.50 No.27

By Michael A. Friedman

Cancer History Project Guest Editorial

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

July 05, 2024

Vol.50 No.27

By Katerina A. Politi and Roy S. Herbst

In the Archives

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

In 1998, lung cancer was the leading cause of cancer deaths in the United States, with 160,000 deaths per year. That statistic inspired Matthew Meyerson, who would soon start working at the Dana-Farber Cancer Institute, to specialize in lung cancer.

July 05, 2024

Vol.50 No.27

In Brief

Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center

Elizabeth Comen, a breast cancer oncologist and women’s health specialist known for her contributions in the field, has joined the Breast Cancer Center at NYU Langone Health’s Perlmutter Cancer Center as an associate professor of medicine.

July 05, 2024

Vol.50 No.27

NCI Trials for August 2021

YOU MAY BE INTERESTED IN

Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

Georgetown’s Zachary Baron on the post-Chevron era: We need guardrails about when agency expertise should be cast aside

A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center

Renew today!

Subscriber content

Login

NCI Trials for August 2021

YOU MAY BE INTERESTED IN

Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

Georgetown’s Zachary Baron on the post-Chevron era: We need guardrails about when agency expertise should be cast aside

A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supplyWarning: This is not a public health recommendation. Do not implement.

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center

Login

A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.